VolitionRx Study Shows Nu.Q Cancer Assay Prognostic Value in Lung Cancer, Paving Way for Reimbursement in France

VolitionRx Limited (NYSE American: VNRX) announced the release of a new clinical study demonstrating the prognostic value of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. Conducted with researchers and clinicians at France’s Hospices Civils de Lyon, the real-world study found that levels of the assay’s H3K27Me3-nucleosome biomarker were associated with cancer stage, overall survival and progression-free survival. A prognostic model incorporating the biomarker and clinical factors successfully stratified patients into low- and high-risk mortality groups. The paper is currently under peer review.

Volition said the findings support the potential use of Nu.Q Cancer to help personalize treatment selection and improve clinical decision-making. The company added that clinical certification of the test at Hospices Civils de Lyon has been completed and that it is preparing a reimbursement submission in France under the RIHN framework. Volition also said it is pursuing commercialization opportunities with hospital networks and potential licensing partners internationally, with reimbursement representing a key milestone toward routine clinical use in France. To view the full press release, visit https://ibn.fm/dhJZ6.

The study's results are significant because they provide evidence that the Nu.Q Cancer Assay can help identify which lung cancer patients are at higher risk of mortality, enabling more aggressive or tailored treatment from the outset. Lung cancer remains the leading cause of cancer death worldwide, and tools that improve risk stratification are urgently needed. By incorporating the Nu.Q biomarker into clinical models, physicians may be able to better predict outcomes and adjust therapies accordingly, potentially improving survival rates and quality of life for patients.

Volition is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. For further information, visit the company’s website at https://volition.com/.

The ability to secure reimbursement in France would be a key step toward routine clinical use of the Nu.Q Cancer Assay. The RIHN framework in France is designed to facilitate access to innovative medical devices, and a successful submission could pave the way for broader adoption in European markets. Volition is also exploring partnerships with hospital networks and licensing opportunities internationally, which could accelerate global availability of the test. The study's peer-review process will further validate the findings and support regulatory and reimbursement decisions.